Method:80 AML patients with high percentage CD34+ was randomly divided into receiving MA/MAE, DA/DAE or HA/HAE induction chemotherapy regimen and evaluate the efficacy and safety.

• 方法:80例免疫分型中有CD34+ 抗原高表达的AML,随机选择(MA/MAE、DA/DAE和HA/HAE)方案,联合化疗1~2个疗程后分别比较CR率、骨髓抑制及其它毒副作用;